AI mental‑health apps show symptom drops
A new empirical study reports AI‑based mental‑health apps reduced anxiety and depression symptoms, adding clinical evidence to digital tools while noting limits like short follow‑up and population diversity gaps. The paper strengthens the case for AI as a scalable adjunct but flags the need for longer, broader trials. (forbes.com)
The trial is listed on ScienceDirect as an exploratory randomized controlled trial of PATH, a tailored LLM‑based mental‑health app, published in the Journal of Affective Disorders listing. (sciencedirect.com) Investigators randomized 316 UK adults aged 19–70 into the study, with 201 female and 115 male participants reported in baselines. (eurekamag.com) Participants were allocated to PATH versus an NHS self‑help website control and outcomes were measured by GAD‑7 and PHQ‑9 at baseline, two weeks and eight weeks. (academic.oup.com) At the two‑week assessment the PATH arm showed significantly lower GAD‑7 and PHQ‑9 scores with medium effect sizes, and by eight weeks those who continued app use exhibited larger reductions in both anxiety and depression. (sciencedirect.com) The protocol’s follow‑up window ended at eight weeks and the sample was UK‑only with a female majority, factors the authors note constrain external validity for other populations and longer‑term outcomes. (academic.oup.com) Coverage and the paper both emphasize that PATH was a single, customized deployment and call for longer, multisite replications with more diverse cohorts before scaling the model as a general solution. (forbes.com)
